After this evening's 4.0% surge to $261.62 per share, Jazz Pharmaceuticals might just keep moving past its target price of $266.9. With an average analyst rating of buy, and target prices from $196.0 to $307.0, the stock's next move is anyone's guess.
The stock has an average amount of shares sold short at 6.2%, and a short ratio of 4.42. The company's insiders own 3.07% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 107.7% of Jazz Pharmaceuticals's shares being owned by this investor type.
Institutions Invested in Jazz Pharmaceuticals
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2026-03-31 | Blackrock Inc. | 9% | 5,591,700 | $1,462,900,526 |
| 2026-03-31 | Vanguard Portfolio Management LLC | 5% | 2,983,242 | $780,475,757 |
| 2026-03-31 | Capital World Investors | 4% | 2,673,376 | $699,408,616 |
| 2026-03-31 | Vanguard Capital Management LLC | 4% | 2,648,333 | $692,856,866 |
| 2026-03-31 | LSV Asset Management | 4% | 2,386,840 | $624,445,069 |
| 2026-03-31 | FMR, LLC | 4% | 2,275,762 | $595,384,843 |
| 2026-03-31 | Franklin Resources, Inc. | 3% | 1,958,940 | $512,497,873 |
| 2026-03-31 | Dimensional Fund Advisors LP | 3% | 1,895,215 | $495,826,139 |
| 2026-03-31 | State Street Corporation | 3% | 1,891,646 | $494,892,417 |
| 2026-03-31 | EcoR1 Capital, LLC | 3% | 1,706,469 | $446,446,411 |
Besides an analyst consensus of some upside potential, other market factors point to there being positive market sentiment on Jazz Pharmaceuticals.
